Waldenström Macroglobulinemia

NEW ORLEANS — Breakthrough COVID infection rates in patients with hematologic malignancies did not correlate with anti-spike antibody levels, suggesting mRNA vaccines may have lost efficacy against the omicron strain, according to a study.

Three-quarters of patients with advanced B-cell malignancies who received an investigational chimeric antigen receptor T-cell therapy achieved complete response, according to the agent’s manufacturer.

The FDA granted orphan drug designation to several therapies in development for oncology indications.

The FDA approved zanubrutinib for adults with Waldenström macroglobulinemia.

The addition of copanlisib to rituximab extended PFS among patients with relapsed indolent non-Hodgkin lymphoma who received prior rituximab-containing therapy, according to topline data released by the agent’s manufacturer.

Dana-Farber Cancer Institute announced the launch of a randomized clinical trial evaluating the use of ibrutinib — an oral medication used to treat blood cancer — in patients with COVID-19.

ORLANDO — Autologous and allogeneic hematopoietic stem cell transplantation both conferred encouraging survival outcomes among patients with Waldenström macroglobulinemia, according to results of a systematic review and meta-analysis presented at TCT | Transplantation & Cellular Therapy Meetings.

The FDA granted orphan drug designation to CLR 131 for treatment of lymphoplasmacytic lymphoma.